Alyftrek to be Listed on the PBS
From 1 February 2026, Alyftrek will be listed on the Pharmaceutical Benefits Scheme (PBS), making this next-generation treatment more accessible to eligible Australians aged six and over.
Alyftrek is the newest prescription medicine for people aged six years and older with CF with at least one responsive CFTR gene mutation. It combines three active ingredients – vanzacaftor, tezacaftor and deutivacaftor – that work together to directly target the underlying genetic cause of the condition.
Alyftrek is the first once-daily CFTR modulator, indicated for a broad range of CFTR gene mutations. Its three active ingredients work together to better control mucus production, supporting better lung and digestive function. The once-daily dose may also make it easier for people to maintain their treatment routine. As the latest, next generation treatment it will help ensure that people living with CF have the most effective therapies they need.
This PBS listing is for people with at least one responsive CFTR gene mutation, opening the door to treatment for more Australians and representing a major step toward more equitable access to cutting-edge CF therapies nationwide.
More information here.